Extensions

To detail the patent term adjustments (PTA), patent term extensions (PTE), continuation applications, divisional applications, related family members, and the projected expiration date for US patent 12214225, I will use the authoritative patent text and information from USPTO databases.

Patent Term Adjustment (PTA)

Patent Term Adjustment (PTA) compensates for administrative delays by the USPTO during the prosecution of a patent application. It adds days to the 20-year lifespan of the patent. These delays can include the USPTO failing to:

• Issue a first office action within 14 months of filing.
• Respond to an applicant's reply or appeal within four months.
• Act on an application within four months after a PTAB or federal court decision.
• Issue a patent within four months after payment of the issue fee.
• Issue a patent within 36 months of its actual filing date.

The provided patent text for US12214225 does not explicitly state the amount of Patent Term Adjustment granted. To determine the exact PTA, the patent's prosecution history would need to be reviewed, typically through USPTO Patent Center or Patent Public Search. However, since the patent was filed on August 21, 2024, and granted on February 4, 2025, it was prosecuted relatively quickly (less than 6 months). Such a short prosecution period typically results in minimal or no PTA.

Patent Term Extension (PTE)

Patent Term Extension (PTE) is available under 35 U.S.C. § 156, primarily for patents claiming products (e.g., human and veterinary pharmaceuticals, food/color additives, medical devices) that require regulatory approval before commercial marketing. PTE aims to restore a portion of the patent term lost during the regulatory review process. The maximum extension is five years, and the total post-approval patent life cannot exceed 14 years from the date of FDA approval.

The patent US12214225, titled "Methods for fixing hair and skin," describes compositions for treating hair and skin. These types of cosmetic applications may not typically fall under the categories for which PTE is granted (FDA-approved drugs, medical devices, etc.). There is no indication in the provided text that US12214225 has sought or been granted a Patent Term Extension.

Continuation and Divisional Applications

The provided patent text states that US12214225 is a continuation of several prior applications. This indicates a family of related patents and applications.

• US12214225B2 is a continuation of U.S. application Ser. No. 18/177,011 filed Mar. 1, 2023.
• U.S. application Ser. No. 18/177,011 is a continuation of U.S. application Ser. No. 17/941,675 filed Sep. 9, 2022.
• U.S. application Ser. No. 17/941,675 is a continuation of U.S. application Ser. No. 16/830,789 filed Mar. 26, 2020 (now U.S. Pat. No. 11,446,525).
• U.S. application Ser. No. 16/830,789 is a continuation of U.S. application Ser. No. 15/854,504 filed Dec. 26, 2017 (now U.S. Pat. No. 10,639,505).
• U.S. application Ser. No. 15/854,504 is a continuation of U.S. application Ser. No. 14/835,223 filed Aug. 25, 2015 (now U.S. Pat. No. 9,855,447).
• U.S. application Ser. No. 14/835,223 is a continuation of U.S. application Ser. No. 14/748,831 filed Jun. 24, 2015 (now U.S. Pat. No. 9,144,537).
• U.S. application Ser. No. 14/748,831 is a continuation of U.S. application Ser. No. 14/459,012 filed Aug. 13, 2014 (now U.S. Pat. No. 9,095,518).
• U.S. application Ser. No. 14/459,012 is a continuation-in-part of International Application PCT/US2014/049388 filed Aug. 1, 2014.

The patent text does not explicitly mention any divisional applications.

Related Family Members

The patent explicitly lists several priority applications, which are related family members:

• U.S. Prov. Application 61/861,281 filed Aug. 1, 2013.
• U.S. Prov. Application 61/867,872 filed Aug. 20, 2013.
• U.S. Prov. Application 61/885,898 filed Oct. 2, 2013.
• U.S. Prov. Application 61/903,239 filed Nov. 12, 2013.
• U.S. application Ser. No. 14/257,089 filed Apr. 21, 2014.
• U.S. application Ser. No. 14/257,056 filed Apr. 21, 2014.
• U.S. application Ser. No. 14/257,076 filed Apr. 21, 2014.
• U.S. Prov. Application 62/000,340 filed May 19, 2014.

Additionally, the patent lists other versions of the publication, which are also related family members:

• US20240408419A1

The "Priority claimed from" section also highlights additional family members:

• US20150037270A1 (from US14/257,076)
• US20150034119A1 (from US14/257,089)
• WO2015017768A1 (from PCT/US2014/049388)
• US9095518B2 (from US14/459,012)
• US20230201632A1 (from US18/177,011)
• US20250302704A1 (from US18/952,929)

Projected Expiration Date

The statutory patent term for utility patents is 20 years from the earliest non-provisional filing date. US12214225 claims priority to U.S. Prov. Application 61/861,281 filed on August 1, 2013. Therefore, the base expiration date (before any adjustments or extensions) would be 20 years from this priority date.

Base expiration date: August 1, 2013 + 20 years = August 1, 2033.

However, the "Anticipated expiration" date listed in the patent information is 2034-04-21. This suggests that there has been Patent Term Adjustment (PTA) granted, adding approximately 8 months and 20 days to the base term (April 21, 2034 - August 1, 2033). Without the detailed PTA calculation, the precise reasons for this adjustment cannot be determined, but it is likely due to USPTO delays during the prosecution of the various applications in its chain, as discussed above.